Skip to main
PHVS

Pharvaris B.V. (PHVS) Stock Forecast & Price Target

Pharvaris B.V. (PHVS) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 67%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Pharvaris NV has significantly increased its global peak sales estimate for deucrictibant to $1.65 billion by 2037, reflecting rising confidence in the drug's market potential. Positive clinical data indicates that 100% of participants in key studies achieved "well-controlled HAE" status and reported improvements in health-related quality of life, suggesting strong therapeutic effectiveness. The estimated prevalence of HAE, combined with the lack of approved therapies, positions deucrictibant favorably for gaining substantial market share if approved, enhancing the company's outlook in the biopharmaceutical sector.

Bears say

Pharvaris NV faces a negative outlook primarily due to the insufficient de-risking of bradykinin B2 receptor antagonism in the chronic prophylaxis setting, which raises questions about the therapeutic effectiveness of their lead candidate. Additionally, the highly competitive market for hereditary angioedema treatment is dominated by established therapies, posing significant challenges for market entry and acceptance of deucrictibant. Compounding these issues, the emergence of multiple subcutaneous therapies set to receive approval within the next three years could further exacerbate the risk of market share erosion for Pharvaris.

Pharvaris B.V. (PHVS) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 67% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pharvaris B.V. (PHVS) Forecast

Analysts have given Pharvaris B.V. (PHVS) a Buy based on their latest research and market trends.

According to 9 analysts, Pharvaris B.V. (PHVS) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pharvaris B.V. (PHVS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.